Long-term survival in a cat with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate

• Main Authors: Johanna E Todd, Sandra M Nguyen
• Format: Article
• Language: English
• Published: SAGE Publishing 2020-06-01
• Series: Journal of Feline Medicine and Surgery Open Reports
• Online Access: https://doi.org/10.1177/2055116920924911

Case summary Primary pancreatic adenocarcinoma is an uncommon neoplasm seen in cats and often has a poor prognosis. We report a case of an 8-year-old male neutered domestic shorthair cat weighing 5.8 kg diagnosed with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate, which had a progression-free interval of 1148 days and survived for more than 1436 days. The treatment was well tolerated; however, the cat developed generalised coat hypopigmentation. Relevance and novel information To our knowledge, the cat in our report has the longest progression-free interval and survival time post-surgical resection of pancreatic carcinoma treated with toceranib. Hypopigmentation as a side effect of toceranib has been reported in dogs, but this is the first case reported in cats.